AR070343A1 - PIRIDINIL AMIDAS, A PROCEDURE FOR THE TREATMENT OF SCHIZOPHRENIA IN A MAMMER AND A PHARMACEUTICAL COMPOSITION - Google Patents

PIRIDINIL AMIDAS, A PROCEDURE FOR THE TREATMENT OF SCHIZOPHRENIA IN A MAMMER AND A PHARMACEUTICAL COMPOSITION

Info

Publication number
AR070343A1
AR070343A1 ARP090100405A ARP090100405A AR070343A1 AR 070343 A1 AR070343 A1 AR 070343A1 AR P090100405 A ARP090100405 A AR P090100405A AR P090100405 A ARP090100405 A AR P090100405A AR 070343 A1 AR070343 A1 AR 070343A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
heteroaryl
aryl
Prior art date
Application number
ARP090100405A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR070343A1 publication Critical patent/AR070343A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0004—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements comprising amorphous/crystalline phase transition cells
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0021—Auxiliary circuits
    • G11C13/0023—Address circuits or decoders
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0021—Auxiliary circuits
    • G11C13/003—Cell access
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L27/00—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate
    • H01L27/02—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers
    • H01L27/04—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body
    • H01L27/10—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body including a plurality of individual components in a repetitive configuration
    • H01L27/102—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body including a plurality of individual components in a repetitive configuration including bipolar components
    • H01L27/1021—Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components specially adapted for rectifying, oscillating, amplifying or switching and having potential barriers; including integrated passive circuit elements having potential barriers the substrate being a semiconductor body including a plurality of individual components in a repetitive configuration including bipolar components including diodes only
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/72—Array wherein the access device being a diode
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/74—Array wherein each memory cell has more than one access device
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/78—Array wherein the memory cells of a group share an access device, all the memory cells of the group having a common electrode and the access device being not part of a word line or a bit line driver
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/79—Array wherein the access device being a transistor
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C5/00—Details of stores covered by group G11C11/00
    • G11C5/02—Disposition of storage elements, e.g. in the form of a matrix array
    • G11C5/025—Geometric lay-out considerations of storage- and peripheral-blocks in a semiconductor storage device
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C5/00—Details of stores covered by group G11C11/00
    • G11C5/06—Arrangements for interconnecting storage elements electrically, e.g. by wiring
    • G11C5/063—Voltage and signal distribution in integrated semi-conductor memory access lines, e.g. word-line, bit-line, cross-over resistance, propagation delay

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Power Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Estos compuestos son utiles en el tratamiento de enfermedades del sistema nervioso central tales como esquizofrenia. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, en la que, L es >C=O, o -SO2-; Y es >C(R7) y la línea discontinua está ausente; o Y es carbono y la discontinua es un doble enlace; o Y es >N- y la línea discontinua está ausente; Z es un enlace, -(C(R2)2)-, -O-, >C=O o -S(O)t-; donde t es un numero entero seleccionado entre 0, 1 o 2; R1 se selecciona entre el grupo compuesto por hidrogeno, -CF3, alquil C1-6-, alquenil C2-6- y alquinil C2-6-; donde cada uno de los mencionados anteriormente alquil C1-6-, alquenil C2-6- y alquinil C2-6- puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; cada R2 se selecciona independientemente entre los radicales compuestos por hidrogeno, halo, -CF3, -CN, -NO2, -(C=O)R8, -(C=O)OR9, -O(C=O)R8, -OR9, -NR10R10, -SR11, -(S=O)R11, -SO2R11, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, cicloalquenil C5-10-, bicicloalquil C6-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3 hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; u opcionalmente R1 y uno de dichos R2 pueden tomarse opcionalmente junto con el carbono o nitrogeno al que están unidos para formar un anillo heterocíclico de 3 a 10 miembros opcionalmente sustituido que contiene opcionalmente uno o dos dobles o triples enlaces y que contiene opcionalmente uno o dos heteroátomos adicionales seleccionados entre N, S y O; u opcionalmente dos de dichos R2 pueden tomarse opcionalmente junto con el carbono al que están unidos para formar un anillo carbocíclico de 3 a 10 miembros opcionalmente sustituido que contiene opcionalmente uno o dos dobles o triples enlaces; y donde dicho anillo carbocíclico de 3 a 10 miembros puede contener opcionalmente 1, 2 o 3 heteroátomos seleccionados independientemente entre N, S y O; R3 se selecciona entre los radicales compuestos por hidrogeno, -CF3, -SOR11, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, cicloalquenil C5-10-, bicicloalquil C6-10-, bicicloalquenil C6-10-, heterocicloalquil C1-9-, heterocicloalquenil C2-9-, heterobicicloalquil C2-9-, heterobicicloalquenil C2-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y -heteroaril C1-9-; cada R4, R5 y R6 se selecciona independientemente entre los radicales compuestos por hidrogeno, halo, -CF3, -CN, -NO2, -(C=O)R8, -(C=O)OR9, -O(C=O)R8, -OCF3, -OR9, -NR10R10, -(NR10)(C=O)R8, -SR11, -(S=O)R11, -SO2R11, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, cicloalquenil C5-10-, bicicloalquil C6-10-, bicicloalquenil C6-10-, heterocicloalquil C1-9-, heterocicloalquenil C2-9-, heterobicicloalquil C2-9-, heterobicicloalquenil C2-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; R7 es hidrogeno, halo, -OR9 o alquil C1-6-; cada R8 se selecciona independientemente entre los radicales compuestos por hidrogeno, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre el grupo compuesto por hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, aril C6-10- y heteroaril C1-9-; cada R9 se selecciona independientemente entre los radicales compuestos por hidrogeno, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9- donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, aril C6-10- y heteroaril C1-9-; cada R10 se selecciona independientemente entre los radicales compuestos por hidrogeno, -SO2-alquilo C1-6, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, cicloalquenil C5-10, aril C6-10- y heteroaril C1-9-; cada R11 se selecciona independientemente entre el grupo compuesto por hidrogeno, amino, alquilamino C1-6-, di(alquil C1-6)amino-, -CF3, alquil C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; n es un numero entero seleccionado entre uno, dos o tres; m es un numero entero seleccionado entre cero, uno, dos, tres o cuatro; p es un numero entero seleccionado entre cero, uno, dos, tres o cuatro; y q es un numero entero seleccionado entre cero, uno, dos, tres o cuatro.These compounds are useful in the treatment of diseases of the central nervous system such as schizophrenia. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein, L is> C = O, or -SO2-; Y is> C (R7) and the dashed line is absent; or Y is carbon and the discontinuous is a double bond; or Y is> N- and the dashed line is absent; Z is a bond, - (C (R2) 2) -, -O-,> C = O or -S (O) t-; where t is an integer selected from 0, 1 or 2; R 1 is selected from the group consisting of hydrogen, -CF 3, C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl; where each of the aforementioned C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl may optionally be substituted with one, two or three substituents independently selected from hydrogen, halo, -CF3, -OCF3, hydroxyl, amino, C1-6 alkylamino, di (C1-6 alkyl) amino-, C1-6 alkyl, C1-6 alkoxy, C3-10- cycloalkyl, C1-9 heterocycloalkyl, C6-10- aryl, and C1 heteroaryl -9-; each R2 is independently selected from the radicals composed of hydrogen, halo, -CF3, -CN, -NO2, - (C = O) R8, - (C = O) OR9, -O (C = O) R8, -OR9 , -NR10R10, -SR11, - (S = O) R11, -SO2R11, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10- cycloalkyl, C5-10 cycloalkenyl, C6 cycloalkyl -10-, C1-9 heterocycloalkyl-, C6-10- aryl and C1-9 heteroaryl; where each of the radicals mentioned above may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, -CF3, -OCF3 hydroxyl, amino, C1-6 alkylamino-, di (C1-6 alkyl) amino- , C1-6- alkyl, C1-6 alkoxy, C3-10- cycloalkyl, C1-9 heterocycloalkyl, C6-10- aryl and C1-9- heteroaryl; or optionally R1 and one of said R2 may optionally be taken together with the carbon or nitrogen to which they are attached to form an optionally substituted 3 to 10 membered heterocyclic ring that optionally contains one or two double or triple bonds and optionally contains one or two additional heteroatoms selected from N, S and O; or optionally two of said R2 may optionally be taken together with the carbon to which they are attached to form an optionally substituted 3 to 10-membered carbocyclic ring that optionally contains one or two double or triple bonds; and wherein said 3 to 10 membered carbocyclic ring may optionally contain 1, 2 or 3 heteroatoms independently selected from N, S and O; R3 is selected from the radicals consisting of hydrogen, -CF3, -SOR11, C1-6- alkyl, C2-6- alkenyl, C2-6- alkynyl, C3-10- cycloalkyl, C5-10- cycloalkenyl, C6-10 alkylcyclo -, C6-10- bicycloalkenyl, C1-9 heterocycloalkyl, C2-9- heterocycloalkenyl, C2-9- heterobicycloalkyl, C2-9- heterobicycloalkenyl, C6-10- aryl and C1-9 heteroaryl; where each of the radicals mentioned above may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, -CF3, -OCF3, hydroxyl, amino, C1-6 alkylamino-, di (C1-6 alkyl) amino -, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 1-10 heterocycloalkyl, C 6-10 aryl, and C 1-9 heteroaryl; each R4, R5 and R6 is independently selected from the radicals composed of hydrogen, halo, -CF3, -CN, -NO2, - (C = O) R8, - (C = O) OR9, -O (C = O) R8, -OCF3, -OR9, -NR10R10, - (NR10) (C = O) R8, -SR11, - (S = O) R11, -SO2R11, C1-6- alkyl, C2-6 alkenyl, C2 alkynyl -6-, C3-10- cycloalkyl, C5-10- cycloalkenyl, C6-10- cycloalkyl, C6-10- cycloalkenyl, C1-9 heterocycloalkenyl, C2-9- heterocycloalkenyl, C2-9 heterobicycloalkyl, C2-9 heterobicycloalkenyl -, C6-10- aryl and C1-9 heteroaryl; where each of the radicals mentioned above may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, -CF3, -OCF3, hydroxyl, amino, C1-6 alkylamino-, di (C1-6 alkyl) amino -, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 1-10 heterocycloalkyl, C 6-10 aryl and C 1-9 heteroaryl; R7 is hydrogen, halo, -OR9 or C1-6 alkyl; each R8 is independently selected from the radicals consisting of hydrogen, C1-6- alkyl, C2-6- alkenyl, C2-6- alkynyl, C3-10- cycloalkyl, C1-9- heterocycloalkyl, C6-10- aryl, and C1 heteroaryl -9-; where each of the radicals mentioned above may be optionally substituted with one, two or three substituents independently selected from the group consisting of hydrogen, halo, -CF3, -OCF3, hydroxyl, amino, C1-6 alkylamino, di (C1-alkyl) 6) amino-, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 6-10 aryl and C 1-9 heteroaryl; each R9 is independently selected from the radicals consisting of hydrogen, C1-6- alkyl, C2-6- alkenyl, C2-6- alkynyl, C3-10- cycloalkyl, C1-9- heterocycloalkyl, C6-10- aryl and C1 heteroaryl -9- where each of the above-mentioned radicals may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, -CF3, -OCF3, hydroxyl, amino, C1-6 alkylamino-, di (C1-alkyl) 6) amino-, C 1-6 alkyl, C 1-6 alkoxy, C 3-10 cycloalkyl, C 6-10 aryl and C 1-9 heteroaryl; each R10 is independently selected from the radicals consisting of hydrogen, -SO2-C1-6 alkyl, C1-6- alkyl, C2-6 alkenyl, C2-6- alkynyl, C3-10- cycloalkyl, C6-10- aryl C1-9 heteroaryl; where each of the radicals mentioned above may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, -CF3, -OCF3, hydroxyl, C1-6 alkyl-, C1-6 alkoxy, C3-10 cycloalkyl -, C5-10 cycloalkenyl, C6-10- aryl and C1-9 heteroaryl; each R11 is independently selected from the group consisting of hydrogen, amino, C1-6- alkylamino, di (C1-6 alkyl) amino-, -CF3, C1-6 alkyl-, C3-10- cycloalkyl, C1-9 heterocycloalkyl- , C6-10- aryl and C1-9- heteroaryl; n is an integer selected from one, two or three; m is an integer selected from zero, one, two, three or four; p is an integer selected from zero, one, two, three or four; and q is an integer selected from zero, one, two, three or four.

ARP090100405A 2008-02-05 2009-02-05 PIRIDINIL AMIDAS, A PROCEDURE FOR THE TREATMENT OF SCHIZOPHRENIA IN A MAMMER AND A PHARMACEUTICAL COMPOSITION AR070343A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2619508P 2008-02-05 2008-02-05

Publications (1)

Publication Number Publication Date
AR070343A1 true AR070343A1 (en) 2010-03-31

Family

ID=40680365

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100405A AR070343A1 (en) 2008-02-05 2009-02-05 PIRIDINIL AMIDAS, A PROCEDURE FOR THE TREATMENT OF SCHIZOPHRENIA IN A MAMMER AND A PHARMACEUTICAL COMPOSITION

Country Status (11)

Country Link
US (1) US20090197859A1 (en)
EP (1) EP2265600A1 (en)
JP (1) JP2011511056A (en)
AR (1) AR070343A1 (en)
CA (1) CA2714232A1 (en)
CL (1) CL2009000245A1 (en)
PA (1) PA8815001A1 (en)
PE (1) PE20091379A1 (en)
TW (1) TW200938532A (en)
UY (1) UY31632A1 (en)
WO (1) WO2009098576A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CA2739916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
AR076766A1 (en) 2009-05-14 2011-07-06 Japan Tobacco Inc AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE TREATMENT OF AUTOIMMUNE DISEASES.
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
JO3250B1 (en) 2009-09-22 2018-09-16 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
KR20110123657A (en) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
EP2576539B1 (en) 2010-05-27 2017-12-13 Bayer CropScience AG Pyridinyl carbonic acid derivatives as fungicides
EP2632253B1 (en) * 2010-10-29 2016-04-06 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
SI2909192T1 (en) 2012-10-16 2017-08-31 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
KR20150070348A (en) 2012-10-16 2015-06-24 얀센 파마슈티카 엔.브이. Heteroaryl linked quinolinyl modulators of rorγt
SG11201502935VA (en) 2012-10-16 2015-09-29 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror-gamma-t
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP2016511761A (en) * 2013-02-14 2016-04-21 ガルデルマ・リサーチ・アンド・デヴェロップメント Method for synthesizing 4-piperidin-4-yl-benzene-1,3-diol and salts thereof, and novel compound tert-butyl 4- (2,4-dihydroxy-phenyl) -4-hydroxy-piperidine-1-carboxylate
JP2016509043A (en) * 2013-02-21 2016-03-24 セルビタ エス．エー． Pyridine derivatives as 5-HT6 receptor antagonists
WO2014176142A1 (en) * 2013-04-23 2014-10-30 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
BR112016008258A2 (en) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv quinolinyl ror? t modulators
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
TW201811766A (en) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
CN109721530A (en) * 2017-10-31 2019-05-07 成都博腾药业有限公司 A method of preparing the fluoro- 2- pyridine sulfonyl chloride of 6-
EP4003955A1 (en) 2019-07-30 2022-06-01 Karl-Franzens-Universität Graz Inhibitors of human atgl

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) * 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase

Also Published As

Publication number Publication date
CL2009000245A1 (en) 2009-06-05
JP2011511056A (en) 2011-04-07
PE20091379A1 (en) 2009-09-18
US20090197859A1 (en) 2009-08-06
EP2265600A1 (en) 2010-12-29
TW200938532A (en) 2009-09-16
UY31632A1 (en) 2009-09-30
WO2009098576A1 (en) 2009-08-13
PA8815001A1 (en) 2009-09-17
CA2714232A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
AR070343A1 (en) PIRIDINIL AMIDAS, A PROCEDURE FOR THE TREATMENT OF SCHIZOPHRENIA IN A MAMMER AND A PHARMACEUTICAL COMPOSITION
AR119651A1 (en) HETEROCYCLIC AND HETEROARYL COMPOUNDS TO TREAT HUNTINGTON'S DISEASE
AR054560A1 (en) SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AR053652A1 (en) DERIVATIVES OF INDOL AS PROTEIN QUINASE INHIBITORS. PHARMACEUTICAL COMPOSITIONS
AR079231A1 (en) IMIDAZOQUINOLINE DERIVATIVES
AR085615A1 (en) USEFUL FLUOROPIRIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR057380A1 (en) CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE AND THERAPEUTIC USE OF THE SAME
AR054481A1 (en) DERIVATIVES OF 2-AZETIDINONES AS INHIBITORS OF CHOLESTEROL ABSORPTION
AR061369A1 (en) PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
CO6251251A2 (en) DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
ES2668775T3 (en) Tetracyclic compounds
PE20130155A1 (en) ARYLETINYL DERIVATIVES
PE20142456A1 (en) OXAZOLIDIN-2-ONA COMPOUNDS AND USES OF THE SAME AS INHIBITORS OF PI3Ks
PE20140011A1 (en) NOVELTY COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT
AR057072A1 (en) CHEMICAL COMPOUNDS DERIVED FROM 2-AZETIDINONE, PHARMACEUTICAL FORMULATION AND A COMPOUND PREPARATION PROCESS
AR080596A1 (en) RENTAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
ES2393824T3 (en) Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
AR079205A1 (en) MORPHOLINOTIAZOLS AS POSITIVE ALOSTERIC MODULATORS ALFA 7
AR100810A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR075531A1 (en) DERIVATIVES OF PIPERAZIN-CICLOPROPIL BENZAMIDAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM, SUCH AS ALZHEIMER AND SCHIZOPHRENIA, BETWEEN OTHERS
AR060623A1 (en) COMPOUNDS DERIVED FROM 2-AZETIDINONE AND A PREPARATION METHOD
PE20160240A1 (en) NEW DERIVATIVES OF INDOLIZINE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR061111A1 (en) ISOINDOL DERIVATIVES USEFUL TO TREAT PAIN, GASTROINTESTINAL DISORDERS AND CANCER
AR100530A1 (en) ANTIHELMINE COMPOUNDS
AR068115A1 (en) DERIVED FROM PIRAZOLCARBOXILICO ACID PRODUCTION METHOD OF THE SAME AND FUNGICIDE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal